Press Releases Choose Year All Items 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Search Press Releases Found 265 Results April 14, 2025 UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025 March 27, 2025 Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update March 26, 2025 Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 March 25, 2025 Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. February 6, 2025 Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB December 9, 2024 Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017 December 4, 2024 Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance November 19, 2024 Relmada Therapeutics to Present at Jefferies London Healthcare Conference November 14, 2024 Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease November 7, 2024 Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update «...234567...»
